Inactive Instrument

Highlights Generex Biotechnology Corporation Other OTC

Equities

GNBT

US3714853013

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Generex Biotechnology Corporation Enters into Quality Agreement with PPD Development, L.P	21-07-23	CI
Generex Biotechnology Corporation Reports Earnings Results for the Third Quarter Ended April 30, 2021	21-06-21	CI
Generex Biotechnology Corporation Subsidiary NuGenHealth Contracts with Westside Medicine & Cardiology, Inc. to Provide Remote Patient Monitoring Services	21-05-11	CI
Generex Provides Clarification on Its Ii-Key COVID-19 Complete Vaccine China Partnership Agreement	21-05-05	CI
Generex Provides Update on Its Ii-Key COVID-19 Complete Vaccine Program: Advancing Global Development	21-04-27	CI
Generex Biotechnology Corporation Reports Earnings Results for the Second Quarter Ended January 31, 2021	21-03-17	CI
Generex Biotechnology Corporation Completes Mouse Immunogenicity Study	21-02-24	CI
Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for the Complete Vaccine™	20-12-31	CI
Generex Biotechnology Corporation Reports Earnings Results for the First Quarter Ended October 31, 2020	20-12-21	CI
Nugenerex Immuno-Oncology, Inc. and Generex Biotechnology Corporation Signs an Extension for the Receipt of the USD 5,000,000.00 Upfront Licensing Fee Payment	20-12-17	CI
Generex Biotechnology Corporation and Nugenerex Immuno-Oncology Grants Licensing Rights to Bintai Healthcare Sdn Bhd	20-11-25	CI
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribution & Licensing Option for Australia and New Zealand	20-11-23	CI
Generex Biotechnology Corporation Inks $50 Million Licensing Deal with China Partners on the Cooperative Development of the Ii-Key Vaccine Platform	20-11-18	CI
Generex Biotechnology Corporation Reports Earnings Results for the Full Year Ended July 31, 2020	20-11-13	CI
Generex Announces the Signing of A Framework Agreement with the China Cdc, Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co., Ltd on the Cooperative Development of Ii-Key Vaccines	20-11-04	CI
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology, Inc. Sign Distribution and Licensing Agreement with Bintai Healthcare SDN BHD	20-10-09	CI
Bintai Healthcare Sdn Bhd Enters into A Distribution and Licensing Agreement with Generex Biotechnology Corporation and Its Majority Owned Subsidiary, Nugenerex Immuno-Oncology, Inc	20-10-06	CI
Nugenhealth Contracts with Paradise Valley Family Medicine to Provide Chronic Care Management and Remote Patient Monitoring Services	20-09-25	CI
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology, Inc. Sign Agreement with Bintai Kinden Corporation of Malaysia for the Development and Commercialization of the II-Key-SARS-CoV-2 Coronavirus Vaccine	20-09-24	CI
Generex Biotechnology Corporation Signs Binding Licensing & Research Agreement with Bintai Kinden Corporation	20-09-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Generex Biotechnology Corporation Other OTC

Equities

GNBT

US3714853013

Highlights

Filters